Skip to Main Content

Paper Details

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Mol Cancer Res
19
2021
FGFR, HLA, HLA-I, Kidney Cancer, Lenvatinib, PD-L1, PD1, Patients, RCC, VEGFR, advanced RCC, anti-PD-1, cancers, lenvatinib, patient, patients, renal cell carcinoma, tumor
Author NameAffiliation
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Mark LeeMemorial Sloan Kettering Cancer Center
Mark LeeMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Abraham Ari HakimiMemorial Sloan Kettering Cancer Center
Abraham Ari HakimiMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
  • 1 - 18

Datasets

Release 1.2